Carmustine
Back to searchMolecule Structure
Scientific Name
Carmustine
Description of the Drug
Carmustine is an alkylating agent used in the treatment of various malignancies, including brain tumours and multiple myeloma, among others.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00262
http://www.drugbank.ca/drugs/DB00262
Brand Name(s)
Bicnu, Gliadel
Company Owner(s)
Ingenus Pharmaceuticals Llc, Avet Lifesciences Ltd, Navinta Llc, Accord Healthcare Inc, Sti Pharma Llc, Meitheal Pharmaceuticals Inc, Dr Reddys Laboratories Ltd, Amneal Eu Ltd, Jiangsu Hengrui Pharmaceuticals Co Ltd, Azurity Pharmaceuticals Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2311221 |
RNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2311222 |
Glutathione reductase | SINGLE PROTEIN | INHIBITOR | CHEMBL2755 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL4503 | ||||||
PharmGKB | PA448810 | ||||||
Human Metabolome Database | HMDB0014407 | ||||||
DrugBank | DB00262 | ||||||
PubChem: Thomson Pharma | 15171986 | ||||||
PubChem | 2578 | ||||||
Mcule | MCULE-3131772074 | ||||||
LINCS | LSM-6584 | ||||||
Nikkaji | J2.968H | ||||||
BindingDB | 50015950 | ||||||
EPA CompTox Dashboard | DTXSID8022743 | ||||||
DrugCentral | 512 | ||||||
Brenda | 144149 | 9584 | 56876 | 127601 | 18214 | 19848 | 4461 |
ChemicalBook | CB0449612 | ||||||
Guide to Pharmacology | 6800 | ||||||
rxnorm | CARMUSTINE | GLIADEL | BICNU | ||||
KEGG Ligand | C06873 | ||||||
ChEBI | 3423 | ||||||
ZINC | ZINC000003830387 |